當前位置:BPS Bioscience Inc.>>CAR T-Cell Therapy Cell Lines>> 79750LILRB4 NFAT-Luciferase Reporter Jurkat Recombinant Cell Line
Anti-BCMA CAR /NFAT (Luciferase) Re
Anti-CD19 CAR / NFAT (Luciferase) R
Jurkat cells stably expressing human LILRB4 (Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4, GenBank Accession #NM_001278426) and the firefly luciferase gene under the control of NFAT response elements. Activation of NFAT in these cells can be monitored by measuring luciferase activity.
The expression of human LILRB4 was confirmed by flow cytometry analysis. The functionality of the cell line was validated using an anti-CD3 agonist antibody. Treatment of LILRB4-expressing NFAT-Luciferase reporter Jurkat cells with the anti-CD3 agonist antibody induced luciferase activity at a reduced level compared to the same treatment in the NFAT-Luciferase Reporter Jurkat cells (parental cells), consistent with the inhibitory function of LILRB4.
Illustration of the LILRB4 NFAT luciferase reporter Jurkat cell line.
In response to TCR activation, LILRB4 is tyrosine phosphorylated by Src-family kinases such as Lck or Fyn, which triggers recruitment of SH2 domain-containing phosphatases, leading to attenuation of the T cell activation signals.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。